Enhancing FTS (Salirasib) efficiency via combinatorial treatment

Eya Wolfson, Eran Schmukler, Sari Trangle Schokoroy, Yoel Kloog, Ronit Pinkas-Kramarski

Research output: Contribution to journalReview articlepeer-review


The Ras oncogene transmits signals, which regulate various cellular processes including cell motility, differentiation, growth and death. Since Ras signalling is abnormally activated in more than 30% of human cancers, Ras and its downstream signalling pathways are considered good targets for therapeutic interference. Ras is post-translationally modified by the addition of a farnesyl group, which permits its attachment to the plasma membrane. Exploiting this knowledge, a synthetic Ras inhibitor, S-trans, trans-farnesylthiosalicylic acid (FTS; Salirasib), was developed. FTS resembles the farnesylcysteine group of Ras, and acts as an effective Ras antagonist. In the present review, the effect of FTS in combination with various other drugs, as tested in vitro and in vivo, and its therapeutic potential are discussed. As reviewed, FTS cooperates with diverse therapeutic agents, which significantly improves treatment outcome. Therefore, combinations of FTS with other agents have a potential to serve as anti-cancer or anti-inflammatory therapies.

Original languageEnglish
Pages (from-to)130-143
Number of pages14
JournalBiology of the Cell
Issue number5
StatePublished - 1 May 2015


  • Apoptosis
  • Cancer
  • Cell death
  • Diseases
  • G-proteins


Dive into the research topics of 'Enhancing FTS (Salirasib) efficiency via combinatorial treatment'. Together they form a unique fingerprint.

Cite this